Small molecule anti-angiogenic probes of the ubiquitin proteasome pathway: Potential application to choroidal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 9, 2006, Pages 4138-4145

  Bargagna Mohan, Paola ^a   Ravindranath, Padma Priya ^a   Mohan, Royce ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; FIBROBLAST GROWTH FACTOR 2; HEME OXYGENASE 1; I KAPPA B ALPHA; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; VASCULOTROPIN; WITHAFERIN A; WITHANOLIDE D; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; ERGOSTEROL; GROWTH PROMOTOR; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; PLANT EXTRACT;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SUBRETINAL NEOVASCULARIZATION; UBIQUITINATION; WITHANIA SOMNIFERA; CELL CULTURE; CHOROID; CYTOLOGY; DRUG EFFECT; MEDICINAL PLANT; METABOLISM; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULARIZATION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; BLOTTING, WESTERN; CELLS, CULTURED; CHOROID; CHOROIDAL NEOVASCULARIZATION; ENDOTHELIUM, VASCULAR; ERGOSTEROL; GROWTH SUBSTANCES; HEME OXYGENASE-1; HUMANS; I-KAPPA B PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; PLANT EXTRACTS; PLANTS, MEDICINAL; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN; UMBILICAL VEINS;

EID: 33749157379     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1452     Document Type: Article

References (48)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293.
2. Fine SL. Age-related macular degeneration 1969-2004: a 35-year personal perspective. Am J Ophthalmol. 2005;139:405-420.
3. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004;137:496-503.
4. Kijlstra A, La Heij E, Hendrikse F. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 2005;13:3-11.
5. Ambati J, Anand A, Fernandez S, et al. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med. 2003;9:1390-1397.
6. Bok D. Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA. 2005;102:7053-7054.
7. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res. 2001;20:385-414.
8. Cousins SW, Espinosa-Heidmann DG, Csaky KG. Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol 2004;122:1013-1018.
9. Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol. 2006;171:45-56.
10. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537-540.
11. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003;48:2461-2471.
12. Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124:1275-1283.
13. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA. 2005;293:1509-1513.
14. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005;12:1178-1190.
15. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibitors as therapeutics. Essays Biochem. 2005;41:205-218.
16. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23:630-639.
17. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA. 1999;96:10403-10408.
18. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA. 1998;95:15671-15676.
19. Robinson PA, Ardley HC. Ubiquitin-protein ligases: novel therapeutic targets? Curr Protein Pept Sci. 2004;5:163-176.
20. Amit S, Ben-Neriah Y. NF-kappaB activation in cancer: a challenge for ubiquitination- and proteasome-based therapeutic approach. Semin Cancer Biol. 2003;13:15-28.
21. Mishra LC, Singh BB, Dagenais S. Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev. 2000;5:334-346.
22. Korff T, Augustin HG. Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. J Cell Biol. 1998;143:1341-1352.
23. Mohan R, Hammers HJ, Bargagna-Mohan P, et al. Withaferin A is a potent inhibitor of angiogenesis. Angiogenesis. 2004;7:115-122.
24. Sakamoto T, Sakamoto H, Hinton DR, Spec C, Ishibashi T, Ryan SJ. In vitro studies of human choroidal endothelial cells. Curr Eye Res. 1995;14:621-627.
25. Browning AC, Gray T, Amoaku WM. Isolation, culture, and characterisation of human macular inner choroidal microvascular endothelial cells. Br J Ophthalmol 2005;89:1343-1347.
26. Leopold JA, Loscalzo J. Oxidative enzymopathies and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:1332-1340.
27. Prawan A, Kundu JK, Surh AJ. Molecular basis of heme oxygenase-1 induction: implications for chemoprevention and chemoprotection. Antioxid Redox Signal. 2005;7:1688-1703.
28. Su B-Ng J-Q, Kang Y-H, Park E-J, Pezzuto JM, Kinghorn AD. Induction of the phase II enzyme, quinone reductase, by withanolides and norwithanolides from solanaceous species. Rev Organ Chem 2004;1:115-123.
29. Ganzera M, Choudhary MI, Khan IA. Quantitative HPLC analysis of withanolides in Withania somnifera. Fitoterapia. 2003;74:68-76.
30. Sin N, Kim KB, Elofsson M, et al. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg Med Chem Lett. 1999;9:2283-2288.
31. Budhiraja RDK, Pawan SS. Biological activity of withanolides. J Sci Ind Res. 2000;59:904-911.
32. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001;8:759-766.
33. Gupta SK, Mohanty I, Talwar KK, et al. Cardioprotection from ischemia and reperfusion injury by Withania somnifera: a hemodynamic, biochemical and histopathological assessment. Mol Cell Biochem 2004;260:39-47.
34. Ohta K, Yachie A. Development of vascular biology over the past 10 years: heme oxygenase-1 in cardiovascular homeostasis. J Endovasc Ther. 2004;11(suppl 2):140-150.
35. Chen J, Regan RF. Increasing expression of heme oxygenase-1 by proteasome inhibition protects astrocytes from heme-mediated oxidative injury. Curr Neurovasc Res. 2005;2:189-196.
36. Hoekstra KA, Godin DV, Cheng KM. Protective role of heme oxygenase in the blood vessel wall during atherogenesis. Biochem Cell Biol. 2004;82:351-359.
37. Denk A, Goebeler M, Schmid S, et al. Activation of NF-kappa B via the Ikappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. J Biol Chem 2001;276:28451-28458.
38. Verma IM. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann Rheum Dis. 2004;63(suppl 2):57-6l.
39. Madge LA, Pober JS. TNF signaling in vascular endothelial cells. Exp Mol Pathol. 2001;70:317-325.
40. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005;7:758-765.
41. Kayatz P, Heimann K, Schraermeyer U. Ultrastructural localization of light-induced lipid peroxides in the rat retina. Invest Ophthalmol Vis Sci. 1999;40:2314-2321.
42. Wu T, Handa JT, Gottsch JD. Light-induced oxidative stress in choroidal endothelial cells in mice. Invest Ophthalmol Vis Sci. 2005;46:1117-1123.
43. Taylor HR, West S, Munoz B, Rosenthal FS, Bressler SB, Bressler NM. The long-term effects of visible light on the eye. Arch Ophthalmol. 1992;110:99-104.
44. Cruickshanks KJ, Klein R, Klein BE, Nondahl DM. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:246-250.
45. Hammes HP, Hoerauf H, Alt A, et al. N(epsilon)(carboxymethyl)lysin and the AGE receptor RAGE colocalize in age-related macular degeneration. Invest Ophthalmol Vis Sci. 1999;40:1855-1859.
46. Kempe S, Kestler H, Lasar A, Wirth T. NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 2005;33:5308-5319.
47. Frank RN, Amin RH, Puklin JE. Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Am J Ophthalmol. 1999;127:694-709.
48. Sangwan RS, Chaurasiya ND, Misra LN, et al. Phytochemical variability in commercial herbal products and preparations of Withania somnifera (Ashwagandha). Current Science. 2004;86:461-465.